Skip to content

Clinical Study on intervention of Shenling Baigui Granules on Atherosclerosis

Clinical Study on the Regulation of TNF/NF-?B Signaling Pathway by Shenling Baigui Granules to Inhibit Monocyte Adhesion in the Intervention of Atherosclerosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001274
Enrollment
Unknown
Registered
2025-06-26
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Interventions

Intervention group:Shenling Baigui Granules (consisting of 15g Codonopsis pilosula 15g Epimedium brevicornu 15g Phellodendron amurense 15g Angelica sinensis 10g Ligusticum chuanxiong 15g Paeonia lacti

Sponsors

Guang'anmen Hospital Jinan Hospital China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Meets the diagnostic criteria for lower limb arteriosclerotic occlusive disease (Rutherford Stage 0–1) or atherosclerotic carotid artery disease; voluntarily participates in the study and signs an informed consent form; aged 18–75 years.

Exclusion criteria

Exclusion criteria: (1) Patients who have allergic reactions or other adverse reactions to the trial medication; (2) Patients with blood disorders such as coagulation dysfunction anemia or platelet abnormalities; (3) Patients with a history of bleeding disorders in the past three months; (4) Patients with conditions at high risk of major bleeding such as peptic ulcers malignant tumors esophageal varices arteriovenous malformations or vascular aneurysms; (5) Patients with severe comorbidities such as diabetes heart failure cerebral hemorrhage or abnormal liver or kidney function; (6) Patients with inflammatory vascular diseases such as thromboangiitis obliterans Takayasu arteritis or Raynaud's syndrome; (7) Pregnant or breastfeeding women; (8) Patients with psychiatric disorders; (9) Patients whom the investigator deems to have poor compliance and are unlikely to cooperate with the treatment; (10) Patients with incomplete medical records.

Design outcomes

Primary

MeasureTime frame
Serum TNF-a level;

Secondary

MeasureTime frame
blood lipid level;Serum VCAM-1 level;Serum P-selectin level;Serum IL-1ß level;Serum ICAM-1 level;Serum I?Ba level;Serum E-selectin level;Serum NF-?B p65 level;

Countries

China

Contacts

Public ContactYutao WANG

Guang'anmen Hospital Jinan Hospital China Academy of Chinese Medical Sciences

jnwangyutao@163.com15275119546

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026